Search results for "ASPERGILLOSIS"

showing 10 items of 61 documents

Granulocyte functions are independent of arginine availability.

2014

Abstract Arginine depletion via myeloid cell arginase is critically involved in suppression of the adaptive immune system during cancer or chronic inflammation. On the other hand, arginine depletion is being developed as a novel anti-tumor metabolic strategy to deprive arginine-auxotrophic cancer cells of this amino acid. In human immune cells, arginase is mainly expressed constitutively in PMNs. We therefore purified human primary PMNs from healthy donors and analyzed PMN function as the main innate effector cell and arginase producer in the context of arginine deficiency. We demonstrate that human PMN viability, activation-induced IL-8 synthesis, chemotaxis, phagocytosis, generation of RO…

ArginineHydrolasesNeutrophilsPhagocytosisImmunologyPrimary Cell CultureInflammationAntineoplastic AgentsApoptosisBiologyPharmacologyArgininePolyethylene GlycolsMiceImmune systemPhagocytosismedicineImmunology and AllergyAnimalsHumansLungCells CulturedRespiratory BurstInnate immune systemArginaseAspergillus fumigatusInterleukin-8ChemotaxisCell BiologyAcquired immune systemImmunity InnateArginaseMice Inbred C57BLChemotaxis LeukocyteImmunologyCitrullinePulmonary Aspergillosismedicine.symptomReactive Oxygen SpeciesBronchoalveolar Lavage FluidJournal of leukocyte biology
researchProduct

Azole-resistant Aspergillus fumigatus: A global phenomenon originating in the environment?

2019

Abstract Aspergillus fumigatus is the predominant etiological agent of invasive aspergillosis (IA), a difficult-to-manage fungal disease associated with a high case fatality rate. Azole antifungals, particularly voriconazole, have significantly improved the survival rate of patients with IA. However, the clinical advances made possible through the use of medical azoles could be threatened by the emergence of azole-resistant strains which has been reported in an ever-increasing number of countries over the last 10 years. The major resistance mechanism, that combines point mutation(s) in the coding sequence of cyp51A gene and an insertion of a tandem repeat in the promoter region of this gene…

AzolesAntifungal AgentsGenotypeMicrobial Sensitivity TestsGene mutationAspergillosisAspergillus fumigatusMicrobiologyFungal Proteins03 medical and health sciencesDrug Resistance FungalmedicineAspergillosisHumansGeneComputingMilieux_MISCELLANEOUSchemistry.chemical_classificationVoriconazole[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/Health0303 health sciencesbiology030306 microbiologyPoint mutationAspergillus fumigatusbiology.organism_classificationmedicine.disease3. Good healthInfectious DiseaseschemistryAzoleEffluxVoriconazolemedicine.drug
researchProduct

Choosing the Right Antifungal Agent in ICU Patients

2019

Fungi are responsible for around 20% of microbiologically documented infections in intensive care units (ICU). In the last decade, the incidence of invasive fungal infections (IFI), including candidemia, has increased steadily because of increased numbers of both immunocompromised and ICU patients. To improve the outcomes of patients with IFI, intensivists need to be aware of the inherent challenges. This narrative review summarizes the features of routinely used treatments directed against IFI in non-neutropenic ICU patients, which include three classes of antifungals: polyenes, azoles, and echinocandins. ICU patients' pathophysiological changes are responsible for deep changes in the phar…

AzolesAntifungal AgentsReviewKidney Function TestsInvasive aspergillosiEchinocandins0302 clinical medicineLiver Function Tests[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesMedicineDrug InteractionsPharmacology (medical)030212 general & internal medicineComputingMilieux_MISCELLANEOUSmedia_common[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases0303 health sciencesIncidenceIncidence (epidemiology)CandidiasisGeneral MedicineSerum concentrationIntensive care patients3. Good healthIntensive Care UnitsPractice Guidelines as Topic[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCandidiasiNarrative reviewDrug MonitoringInvasive fungi infectionAntifungalDrugmedicine.medical_specialtyIcu patientsmedicine.drug_classmedia_common.quotation_subjectPharmacokineticPolyenesImmunocompromised Host03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIntensive careHumansPharmacokinetics[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyIntensive care medicineIntensive care patient030306 microbiologybusiness.industry[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyInvasive aspergillosisLiver functionbusinessPractical guidelinesInvasive Fungal InfectionsAdvances in Therapy
researchProduct

Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hem…

2014

Background Antifungal prophylaxis is a promising strategy for reducing invasive fungal infections (IFIs) in allogeneic hematopoietic cell transplant (alloHCT) recipients, but the optimum prophylactic agent is unknown. We used mixed treatment comparison (MTC) meta-analysis to compare clinical trials examining the use of oral antifungals for prophylaxis in alloHCT recipients, with the goal of informing medical decision-making. Methods Randomized controlled trials (RCTs) of fluconazole, itraconazole, posaconazole, and voriconazole for primary antifungal prophylaxis were identified through a systematic literature review. Outcomes of interest (incidence of IFI/invasive aspergillosis/invasive can…

Azolesmedicine.medical_specialtyPosaconazolePathologyAntifungal AgentsItraconazoleAspergillosisAntifungalInterquartile rangeInvasive fungal infectionsMixed treatment comparisonInternal medicinemedicineHumansRandomized Controlled Trials as TopicVoriconazolebusiness.industryHematopoietic Stem Cell TransplantationBayes Theoremmedicine.diseaseTransplant RecipientsClinical trialInfectious DiseasesTolerabilityMycosesAlloHCTbusinessFluconazolemedicine.drugResearch ArticleBMC Infectious Diseases
researchProduct

An investigation on the relationship between the occurrence of CMV DNAemia and the development of invasive aspergillosis in the allogeneic stem cell …

2013

Cytomegalovirus (CMV) infection might increase the risk of fungal superinfection in allogeneic stem cell transplant patients. The potential association between the occurrence of CMV DNAemia and the development of invasive aspergillosis in this clinical setting was investigated. The current retrospective observational study included 167 patients undergoing T cell-replete allogeneic stem cell transplantation. Virological monitoring of active CMV infection was performed by the pp65 antigenemia assay and/or by a plasma real-time PCR assay. A total of 109 out of 167 patients developed CMV DNAemia. Twenty-three patients had proven (n = 4) or probable (n = 19) invasive aspergillosis. The occurrenc…

Congenital cytomegalovirus infectionvirus diseasesRetrospective cohort studyDiseaseCmv dnaemiaBiologyAspergillosismedicine.diseasemedicine.disease_causeVirologyTransplantationInfectious DiseasesVirologySuperinfectionmedicineStem cellJournal of Medical Virology
researchProduct

Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole

2003

Managing invasive fungal infections often presents a challenge for clinicians in the treatment of immunocompromised patients. Two very different systemic antifungal agents, voriconazole and caspofungin, have recently been introduced into the market place. Voriconazole is a new triazole antifungal, while caspofungin is the first echinocandin antifungal. Voriconazole acts by inhibiting the synthesis of ergosterol in the fungal cell membrane. Caspofungin inhibits beta-1,3-D-glucan synthesis in the cell wall, a target present in fungal cells, but absent from mammalian cells. Both agents are broad-spectrum, with efficacy against invasive Aspergillus and Candida infections. The safety and tolerab…

DrugAntifungal AgentsEchinocandinmedia_common.quotation_subjectPharmacologyPeptides CyclicEchinocandinsLipopeptideschemistry.chemical_compoundCaspofunginpolycyclic compoundsmedicineAspergillosisHumansDrug InteractionsAdverse effectmedia_commonVoriconazoleClinical Trials as Topicbusiness.industryCandidiasisGeneral MedicineTriazolesDrug interactionClinical trialPyrimidinesTreatment OutcomeTolerabilitychemistryVoriconazoleCaspofunginPeptidesbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Binding of human fibronectin to Aspergillus fumigatus conidia.

1996

Aspergillus fumigatus conidia exhibited the ability to bind purified human fibronectin, whereas mycelial forms did not bind the ligand, as detected by an indirect immunofluorescence assay with an antifibronectin polyclonal antibody after incubation of the cells with fibronectin. Flow cytometry confirmed that binding of the ligand to conidia was dose dependent and saturable. Pretreatment of the cells with trypsin markedly reduced binding, which suggested a protein nature for the binding sites present at the surface of conidia. Intact conidia were also able to adhere to fibronectin or antifibronectin antibodies, a significant reduction (from 88 to 92%) in the binding of conidia was noticed, t…

ImmunologyMicrobiologyAspergillus fumigatusFungal ProteinsMicemedicineAnimalsAspergillosisHumansTrypsinBinding siteGel electrophoresisFungal proteinbiologyAspergillus fumigatusLigand (biochemistry)biology.organism_classificationTrypsinFlow CytometryFibronectinsFibronectinInfectious DiseasesBiochemistryPolyclonal antibodiesbiology.proteinParasitologymedicine.drugResearch ArticleInfection and immunity
researchProduct

Clinical risk factors for invasive aspergillosis in lung transplant recipients: Results of an international cohort study

2018

BACKGROUND: Invasive aspergillosis (IA) is a frequent complication in lung transplant recipients (LTRs). Clinical risk factors for IA have not been fully characterized, especially in the era of extensive anti-fungal prophylaxis. The primary objective of this study was to evaluate the clinical risk factors associated with IA in LTRs. The secondary objective was to assess the mortality in LTRs who had at least 1 episode of IA compared with LTRs who never had experienced IA.METHODS: We conducted an international, multicenter, retrospective cohort study of 900 consecutive adults who received lung transplants between 2005 and 2008 with 4years of follow-up. Risk factors associated with IA were id…

Male0301 basic medicineAntifungal Agentsviruses030230 surgeryAspergillosisanti-fungal prophylaxis; Aspergillus spp; invasive aspergillosis; lung transplant recipient; single-lung transplant; Surgery; Pulmonary and Respiratory Medicine; Cardiology and Cardiovascular Medicine; TransplantationCohort StudiesPostoperative Complications0302 clinical medicineRisk Factorshemic and lymphatic diseasesMedicineInvasive Pulmonary AspergillosisFirst episodeMortality rateHazard ratioMiddle Agedembryonic structuresFemaleCardiology and Cardiovascular MedicineLung TransplantationCohort studyAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyanimal structuresAdolescent030106 microbiologyYoung Adult03 medical and health sciencesanti-fungal prophylaxisInternal medicineHumansIntensive care medicineAgedProportional Hazards ModelsRetrospective Studiesinvasive aspergillosisTransplantationbusiness.industryProportional hazards modelAspergillus fumigatusAspergillus spp anti-fungal prophylaxis invasive aspergillosis lung transplant recipient single-lung transplantAspergillus sppRetrospective cohort studybiochemical phenomena metabolism and nutritionmedicine.diseaseSurvival Analysissingle-lung transplantTransplantationSurgerybusinesslung transplant recipientFollow-Up StudiesThe Journal of Heart and Lung Transplantation
researchProduct

Pulmonary infiltrate with characteristic “reversed halo” and “air crescent” signs

2016

Male0301 basic medicinePathologymedicine.medical_specialtyAntifungal AgentsPancytopenia030106 microbiologyAstrocytoma030218 nuclear medicine & medical imagingImmunocompromised Host03 medical and health sciences0302 clinical medicineBronchoscopyInternal MedicineHumansMedicineInvasive Pulmonary Aspergillosisbusiness.industryMiddle AgedCombined Modality TherapyAspergillusPulmonary infiltratesVoriconazoleHaloTomography X-Ray Computedbusiness
researchProduct

Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving or…

2015

Studies that analyze the epidemiology and risk factors for invasive fungal disease (IFD) after engraftment in alloSCT are few in number. This single-center retrospective study included 404 alloSCT adult recipients surviving > 40 days who engrafted and were discharged without prior IFD. All patients who received >= 20 mg/day of prednisone were assigned to primary oral prophylaxis (itraconazole or low-dose voriconazole). The primary end point was the cumulative incidence (CI) of probable/proven IFD using the European Organization for Research and Treatment of Cancer and Mycoses Study Group (EORTC/MSG) criteria. The independent prognostic factors after multivariate analyses were used to constr…

MaleAntifungal AgentsTransplantation ConditioningPremedicationmedicine.medical_treatmentMULTICENTERAdministration OralHematopoietic stem cell transplantationEchinocandinsCOMPETING RISKCaspofunginRisk FactorsCause of DeathINFECTIONGranulocyte Colony-Stimulating FactorEPIDEMIOLOGYCumulative incidenceTreatment FailureFramingham Risk ScoreIncidenceIncidence (epidemiology)Hematopoietic Stem Cell TransplantationHematologyMiddle AgedAllograftsHematologic NeoplasmsVORICONAZOLEDrug Therapy CombinationFemaleASPERGILLOSISRisk assessmentFungemiamedicine.drugAdultmedicine.medical_specialtyNeutropeniaANTIFUNGAL PROPHYLAXISNeutropeniaRisk AssessmentITRACONAZOLEMedication AdherenceImmunocompromised HostLipopeptidesYoung AdultAmphotericin BInternal medicinemedicineAspergillosisHumansAgedRetrospective StudiesVoriconazoleTransplantationbusiness.industryRetrospective cohort studyFLUCONAZOLETriazolesmedicine.diseaseSurvival AnalysisSurgeryMycosesPatient CompliancebusinessSCT
researchProduct